Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.

IIBSP-MAS-2025-133

The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.

Inclusion Criteria:

• Patients will be included who are able to provide informed consent and actively participate in periodic assessments.

Exclusion Criteria:

• Risky alcohol consumption:

> 30 g/day in men and > 20 g/day in women. AUDIT score: > 7 points in men, > 5 in women.

• Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.).
• Advanced neurodegenerative diseases or severe psychiatric disorders.
• Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.